Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia - Logunov, D Y; Dolzhikova, I V; Zubkova, O V (Lancet (London, England), 2020)
. doi:10.1016/S0140-6736(20)31866-3